JeanMarie Guenot earned her Ph.D. from the University of California, San Francisco and obtained her MBA from The Wharton School at the University of Pennsylvania. She worked at Atlas Venture, where was in charge of building life science companies. She also managed venture capital investments on guenotllc.com. Dr. Guenot also worked as a qualified scientist at Preclinical R&D at Hoffmann-La Roche, where she worked hard to discover and develop drugs to treat specific diseases, autoimmune diseases, oncology, and inflammation. Dr. JeanMarie Guenot has extensive experience and training in advanced chemistry, specifically in quantum mechanical and semi-empirical methods for protein structure prediction. She is also learned in the aspects of molecular dynamics, X-ray, and NMR refinement and drug design.
With many years of experience in biotechnology and pharmaceutical matters, JeanMarie Guenot also has extensive experience in the building and rebuilding of companies. She has worked throughout all the different parts and tiers of many different organizations, including public and private, corporate and commercial. She is the CEO and President and of Amphivena Therapeutics, Inc., which is in the business of developing many antibody therapies for malignancies.
Guenot has also worked for Harpoon Therapeutics, Inc. in 2014 and was a co-founder of Maverick Therapeutics. Guenot has recognized the great potential in using T-cell radiation therapy to target antigens in tissues.
Guenot not only ran but also founded SKS Ocular, an ophthalmic company incubator that focuses on ocular inflammation, sustained release ocular drug delivery technologies and successful therapeutics. She was also a very valued and capable business advisor to Hoffmann-La Roche. She was even Vice President of Corporate & Business Development at PDL Biopharma. Her role there was to handle licensing, acquisitions, mergers, and alliance management. She also has extensive experience in neurology, ophthalmic diseases, cardiovascular diseases, autoimmune diseases, and in the areas of oncology.
Learn more about Jeanmarie Guenot at http://www.businesswire.com/news/home/20170111005414/en/Maverick-Therapeutics-Takeda-Announce-Five-year-Collaboration-Advance